

Abstract	Title	Presentation Timing (ET)
<u>Oral Presentations</u>		
AL Amyloidosis		
<u>696</u>	First 20-Patient Safety and Efficacy Data from Nexicart-2, The First U.S. Trial of CAR-T in R/R Light Chain (AL) Amyloidosis, NXC-201	Sunday, December 7, 2025, 5:45-6 p.m.
B-Cell Acute Lymphoblastic Leukemia		
<u>163</u>	High Event-Free (EFS) and Overall Survival (OS) After Non-Total Body Irradiation (TBI) Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Next-Generation-Sequencing Minimal Residual Disease (NGS-MRD) Negative B-Acute Lymphoblastic Leukemia (B-ALL): Results from the EndRAD Trial (PTCTC ONC1701)	Saturday, December 6, 2025, 12-12:15 p.m.
<u>329</u>	Molecular and Functional Determinants of Response to Venetoclax and Inotuzumab Ozogamicin in CD22-Positive ALL	Saturday, December 6, 2025, 5-5:15 p.m.
<u>333</u>	Immunoglobulin Variable Gene Diversity Reflects Distinct Metabolic/Signaling States and Impacts Measurable Residual Disease Monitoring and Clinical Outcome in B-Cell Acute Lymphoblastic Leukemia	Saturday, December 6, 2025, 5-5:15 p.m.
<u>441</u>	Primary Efficacy Analysis of Phase II Study Investigating Tyrosine Kinase Inhibitor (TKI) and Inotuzumab Ozogamicin-Based Therapy for Newly Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)	Sunday, December 7, 2025, 10-10:15 a.m.
<u>443</u>	CD19-CAR T Cell Therapy as a Definitive Consolidation in Older Adults with B-ALL in CR1 is Safe and Induces Durable MRD-Remission	Sunday, December 7, 2025, 10:30-10:45 a.m.
<u>511</u>	Bone Marrow Next Generation Sequencing Minimal Residual Disease (NGS-MRD) Positivity Pre-ALlogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcomes for Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Planned Analysis from The PTCTC ONC1401 Trial	Sunday, December 7, 2025, 9:30-9:45 a.m.
<u>550</u>	Pre-CAR Next Generation Sequencing Informs Patient Outcomes in Children and Young Adults with B-Acute Lymphoblastic Leukemia	Sunday, December 7, 2025, 12:45-1 p.m.
<u>551</u>	A Comprehensive Analysis of PCR for BCR::ABL1 and Next-Generation Sequencing (NGS) Based Measurable Residual Disease (MRD) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Prevalence, Association with Transcript Type, and Clinical Outcomes	Sunday, December 7, 2025, 1-1:15 p.m.
<u>645</u>	Venetoclax Plus inotuzumab Ozogamicin for Relapsed and Refractory ALL: Results of a Phase I Trial	Sunday, December 7, 2025, 5- 5:15 p.m.

758	Blinatumomab Mitigates the Impact of Traditional Adverse Prognosticators Among Children with Standard Risk B-Acute Lymphoblastic Leukemia: Updated Results of The Children's Oncology Group (COG) Trial AALL1731	Monday, December 8, 2025, 10:45-11 a.m.
T-Cell Acute Lymphoblastic Leukemia		
644	Outcome of Children and Adolescents with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001	Sunday, December 7, 2025, 4:45-5 p.m.
Chronic Lymphocytic Leukemia		
680	Time-Limited Pirtobrutinib, Venetoclax, and Obinutuzumab Combination in First-Line Chronic Lymphocytic Leukemia	Sunday, December 7, 2025, 4:45-5 p.m.
793	MRD-Guided Therapy of Sonrotoclax (BGB-11417) + Obinutuzumab (O) in Patients with Treatment-Naive CLL: Initial Results from an Ongoing Phase 1/1b Study, BGB-11417-101	Monday, December 8, 2025, 10:30-10:45 a.m.
Diffuse Large B-Cell Lymphoma		
941	Redefining Post-CD19 CAR T-Cell Surveillance with ctDNA: Real-World insights From Post Axi-Cel and Liso-Cel Therapy	Monday, December 8, 2025, 2:45-4:15 p.m.
Follicular Lymphoma		
465	Epcoritamab with Rituximab + Lenalidomide (R2) and Epcoritamab Maintenance Deliver Deep and Durable Remissions in Previously Untreated (1L) Follicular Lymphoma (FL): 3-Year Outcomes from Epcore NHL-2 Arms 6 and 7	Sunday, December 7, 2025, 10-10:15 a.m.
Mantle Cell Lymphoma		
662	High Complete Response Rates and Minimal Residual Disease (MRD) Negativity, with Durable Responses, in High-Risk Mantle Cell Lymphoma (MCL) with GLPG5101, A Fresh, Early Memory-Enriched CAR T-Cell Therapy with A 7-Day Vein-To-Vein Time: Results from the ATALANTA-1 MCL Cohort	Sunday, December 7, 2025, 4:45-5 p.m.
664	Phase I/II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)	Sunday, December 7, 2025, 5:15-5:30 p.m.
666	Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel for Frontline Treatment of High-Risk Mantle Cell Lymphoma: the Window-3 Clinical Trial	Sunday, December 7, 2025, 5:45-6 p.m.
883	Interim Analysis of the Phase II Study of Glofitamab, Lenaliomide and Venetoclax (GLOVe) in Untreated Patients with High-Risk Mantle Cell Lymphoma. Response and Safety Outcomes After the Completion of Stage 1 of 2 Enrollment.	Monday, December 8, 2025, 2:45-3 p.m.

Abstracts Featuring clonoSEQ®
67th American Society of Hematology Annual Meeting & Exposition
Updated: November 24, 2025

<u>888</u>	Preliminary Safety and Efficacy of Boven (Zanubrutinib, Obinutuzumab, and Venetoclax) As Frontline Therapy for Older Patients with Mantle Cell Lymphoma	Monday, December 8, 2025, 4-4:15 p.m.
B-Cell Lymphoma		
<u>268</u>	BAFFR-CAR T Cells (PMB-CT01) Demonstrate Durable Responses and Manageable Toxicities in Relapsed/Refractory B-Cell Lymphomas with Prior CD19-Directed Therapy Failure or CD19-Negative Disease	Saturday, December 6, 2025, 2:45-3 p.m.
Multiple Myeloma		
<u>94</u>	Long Term Progression-Free Survival Benefit with Ciltacabtagene Autoleucel in Standard Risk Relapsed / Refractory Multiple Myeloma	Saturday, December 6, 2025, 10:15-10:30 a.m.
<u>97</u>	Minimal Residual Disease Dynamics in Post-Transplant Patients with Newly Diagnosed Multiple Myeloma Who Received Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in the AURIGA Study	Saturday, December 6, 2025, 9:30-9:45 a.m.
<u>99</u>	Carfilzomib, Lenalidomide, and Dexamethasone (Krd) Versus Bortezomib, Lenalidomide and Dexamethasone (VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) – Interim Results from the Randomized Phase III COBRA Trial.	Saturday, December 6, 2025, 10-10:15 a.m.
<u>248</u>	A Phase 2 Trial of Abbreviated Fixed-Duration (Default 4 Cycles) Linvoseltamab ImmunoConsolidation to Deepen Responses Post Newly Diagnosed Multiple Myeloma Combination Therapy for Minimal Residual Disease Positivity (The IMMUNOPLANT Study)	Saturday, December 6, 2025, 2:15-2:30 p.m.
<u>252</u>	Tumor Clearance, T-Cell Fitness, and Minimal Residual Disease (MRD) Outcomes in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Cevostamab Plus Pomalidomide and Dexamethasone: Biomarker Analyses from CAMMA 1 Arm B	Saturday, December 6, 2025, 3:15-3:30 p.m.
<u>251</u>	A Phase 2 Trial of Iberdomide, Carfilzomib, Daratumumab and Dexamethasone Quadruplet Therapy for Relapsed/Refractory Multiple Myeloma: the Rekindle Study	Saturday, December 6, 2025, 3-3:15 p.m.
<u>256</u>	Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Updated Results From iMMagine--1	Saturday, December 6, 2025, 2:45-3 p.m.
<u>269</u>	Safety and Efficacy of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-Cell Therapy, in Relapsed/Refractory Multiple Myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 Study	Saturday, December 6, 2025, 3-3:15 p.m.
<u>363</u>	Distinct Trajectory and Prognosis of Measurable Residual Disease (MRD) in t(11;14) Multiple Myeloma (Mm) Treated with Upfront Quadruplet (QUAD) Therapy and Autologous Stem Cell Transplantation (ASCT)	Saturday, December 6, 2025, 4:30-4:45 p.m.

Abstracts Featuring clonoSEQ®
67th American Society of Hematology Annual Meeting & Exposition
Updated: November 24, 2025

368	Sustained Minimal Residual Disease (sMRD) Negativity in Transplant ineligible Newly Diagnosed Multiple Myeloma Treated with Isatuximab Plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) Versus Isa-Rd: 12-24-Month Data from the Phase 3 Benefit Trial (IFM 2020-05)	Saturday, December 6, 2025, 4:15-4:30 p.m.
497	Longitudinal Assessments of Minimal Residual Disease in High-Risk Patients from Benefit Phase 3 Randomized Study of Isatuximab Plus Lenalidomide and Dexamethasone with Bortezomib (IsaVRd) Versus Isard in Newly Diagnosed Transplant Ineligible Multiple Myeloma. (IFM 2020-05)	Sunday, December 7, 2025, 10:30-10:45 a.m.
697	Safety and Efficacy of Linvoseltamab as a Simplified Monotherapy First-Line Regimen in NDMM: initial Results from the Window of Opportunity Phase 1/2 LINKER-MM4 Trial	Sunday, December 7, 2025, 4:30-4:45 p.m.
699	Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety, Efficacy, and Correlative Data from the “STEM” (Sequential T Cell-Engagement for Myeloma) Trial	Sunday, December 7, 2025, 5- 5:15 p.m.
700	Subcutaneous Cevostamab Demonstrates Manageable Safety and ClinicALLY Meaningful Activity in Relapsed/Refractory Multiple Myeloma (RRMM): First Results from the Phase Ib CAMMA 3 Study	Sunday, December 7, 2025, 5:15-5:30 p.m.
Poster Presentations		
B-Cell Acute Lymphoblastic Leukemia		
1558	Latency Between Detectable Low-Level Measurable Residual Disease (MRD) By Next Generation Sequencing and Overt Relapse Following Flow Cytometry MRD-Negative Remission in Patients with Acute Lymphoblastic Leukemia: Implications for the Optimal Frequency of MRD Monitoring	Saturday, December 6, 2025, 5:30-7:30 p.m.
1566	Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis	Saturday, December 6, 2025, 5:30-7:30 p.m.
1567	The Addition of Inotuzumab Ozogamicin to Frontline Hyper-CVAD and Sequential Blinatumomab Leads to Durable Survival Outcomes in Adults with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Four-Year Follow-Up of a Phase 2 Study	Saturday, December 6, 2025, 5:30-7:30 p.m.
1571	Blinatumomab and Ponatinib Demonstrates Ongoing Efficacy as Frontline Therapy in Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-Up from a Phase 2 Study	Saturday, December 6, 2025, 5:30-7:30 p.m.
1573	Brexucabtagene Autoleucel (Brexucel) as a Consolidation Therapy in B-Cell Acute Lymphoblastic Leukemia (B-ALL) Post HCVAD/miniHCVD-Inotuzumab-Blinatumomab Regimens: Initial Results of a Prospective Phase 2 Trial.	Saturday, December 6, 2025, 5:30-7:30 p.m.
1575	Updated Results of a Phase II Study of Blinatumomab in Adults with Measurable Residual Disease of 10 ⁻⁴ or Higher	Saturday, December 6, 2025, 5:30-7:30 p.m.

Abstracts Featuring clonoSEQ®
67th American Society of Hematology Annual Meeting & Exposition
Updated: November 24, 2025

<u>3326</u>	Safety and Efficacy of Carniospinal Irradiation (CSI) Before CAR T Cell Therapy in Patients with Acute Lymphoblastic Leukemia (ALL) with Central Nervous System (CNS) Disease: A Potential Role for CSI Beyond Cell Killing and Into Immune Priming	Sunday, December 7, 2025, 6-8 p.m.
<u>3339</u>	Optimal Therapy for Pediatric B-ALL in First Relapse: Comparative Effectiveness of Blinatumomab to Hematopoietic Cell Transplantation Versus CD19 CAR T Cell Therapy	Sunday, December 7, 2025, 6-8 p.m.
<u>3345</u>	Safety and Efficacy of Surovatamig (AZD0486) in Adolescent and Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Updated Results from the Phase 1/2 Syrus Study	Sunday, December 7, 2025, 6-8 p.m.
<u>3348</u>	Inotuzumab Ozogamicin Leads to High Rates of Measurable Residual Disease Negativity for Patients with B-Cell Acute Lymphoblastic Leukemia in Morphologic Remission	Sunday, December 7, 2025, 6-8 p.m.
<u>3350</u>	Consolidation with CAR T-Cell Therapy May Abrogate the Need for Allogeneic Stem Cell Transplant in Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia After Receiving Dose-Dense Minihyper-CVD with Inotuzumab Ozogamicin and Blinatumomab	Sunday, December 7, 2025, 6-8 p.m.
<u>3354</u>	Venetoclax in Combination with Dasatinib, Prednisone, Rituximab and Blinatumomab for the Upfront Treatment of Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL), Results from a Phase 1b Study	Sunday, December 7, 2025, 6-8 p.m.
<u>3357</u>	Real World Outcomes of Asciminib in Relapsed/Refractory Philadelphia Chromosome Positive B-ALL and Blast Phase CML	Sunday, December 7, 2025, 6-8 p.m.
<u>3363</u>	Evaluating Flow Cytometry (FC) and Next Generation Sequencing (NGS) For Assessing Minimal Residual Disease (MRD) and B-Cell Aplasia (BCA) in Children, Adolescents and Young Adults (CAYA) with B-Cell Acute Lymphoblastic Leukemia (B-ALL)	Sunday, December 7, 2025, 6-8 p.m.
<u>4165</u>	UCD19 CAR-T Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission with MRD Positivity: Preliminary Results of a Phase I/Ib Clinical Trial	Sunday, December 7, 2025, 6-8 p.m.
<u>4282</u>	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemias of Mixed or Ambiguous Lineage	Sunday, December 7, 2025, 6-8 p.m.
<u>5123</u>	Integrating Next-Generation Sequencing Disease Evaluation and PCR Based CAR-T Cell Tracking to Guide Decision Making in A Real-World Cohort of Pediatric B-Cell ALL Patients.	Monday, December 8, 2025, 6-8 p.m.
<u>5125</u>	A Phase I Study of Venetoclax in Combination with Multiagent Cytotoxic Chemotherapy for Children and Adolescents with Relapsed or Refractory Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia: Results of The Dose Determination Cohort	Monday, December 8, 2025, 6-8 p.m.

Abstracts Featuring clonoSEQ®
67th American Society of Hematology Annual Meeting & Exposition
Updated: November 24, 2025

5128	Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions and Survival in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Long-Term Follow-Up of a Prospective Trial	Monday, December 8, 2025, 6-8 p.m.
5146	Comparison of Paired Bone Marrow and Peripheral Blood Measurable Residual Disease in Pediatric Acute Lymphoblastic Leukemia by Next-Generation Sequencing: A Report from The Dana Farber ALL Consortium Protocol 16-001.	Monday, December 8, 2025, 6-8 p.m.
6038	Incidence and Risk Factors for CNS Relapse in Adult ALL After Allogeneic Hematopoietic Cell Transplant	Monday, December 8, 2025, 6-8 p.m.
Chronic Lymphocytic Leukemia		
3886	Zanubrutinib and Venetoclax As initial Therapy For CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with DetectABLE Minimal Residual Disease (BruVenG)	Sunday, December 7, 2025, 6-8 p.m.
3890	Zanubrutinib + Obinutuzumab + Sonrotoclax in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/SmALL Lymphocytic Lymphoma (TN CLL/SLL): initial Results from an Ongoing Phase 1/1b Study, BGB-11417-101	Sunday, December 7, 2025, 6-8 p.m.
3901	Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting	Sunday, December 7, 2025, 6-8 p.m.
3902	Updated Results from a Phase II Study of Minimal Residual Disease-Guided Venetoclax + Obinutuzumab for the Initial Treatment of Fit Patients with Chronic Lymphocytic Leukemia	Sunday, December 7, 2025, 6-8 p.m.
5676	A Phase II Multicenter Study of Minimal Residual Disease-Guided, Time-Limited Acalabrutinib + Obinutuzumab for the Initial Treatment of Chronic Lymphocytic Leukemia	Monday, December 8, 2025, 6-8 p.m.
Diffuse Large B-Cell Lymphoma		
1964	Split Dose R-CHOP Mitigates Toxicity While Preserving Dose intensity and Response in Frail Elderly Patients with Diffuse Large B Cell Lymphoma (DLBCL) - A Wisconsin Oncology Network (WON) Study	Saturday, December 6, 2025, 5:30-7:30 p.m.
Follicular Lymphoma		
5380	ZAP Trial: MRD-Guided Chemotherapy and Maintenance De-Escalation with Zanubrutinib-GChop in High-Risk FL (Phase II)	Monday, December 8, 2025, 6-8 p.m.
Mantle Cell Lymphoma		
3569	Post-Treatment Outcomes of Tp53-Mutant Mantle Cell Lymphoma Patients Treated with Frontline Zanubrutinib, Obinutuzumab, and Venetoclax (Boven): Durable Responses in Patients Who Achieve Complete Remissions with Undetectable MRD	Sunday, December 7, 2025, 6-8 p.m.

Abstracts Featuring clonoSEQ®
67th American Society of Hematology Annual Meeting & Exposition
Updated: November 24, 2025

3574	Phase II Study of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for the Front-Line Treatment of Mantle Cell Lymphoma (MCL) in Patients ≥60 Years Old; Updated Survival and Minimal Residual Disease (MRD) Analysis of Precog PrE0405	Sunday, December 7, 2025, 6-8 p.m.
3575	Outcomes From the Multicenter ACCRU-LY-1804/Caribou (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-Based Outpatient Therapy) Trial in 1st Line Mantle Cell Lymphoma	Sunday, December 7, 2025, 6-8 p.m.
4159	CD22-Directed CAR-T Cells induce Complete Remissions in High-Risk Follicular and Mantle Cell Lymphoma with Limited Neurotoxicity	Sunday, December 7, 2025, 6-8 p.m.
Multiple Myeloma		
2223	Assessment of Pharmacodynamic Efficacy Biomarkers from a Phase 1, First-in-Human Study of Arlocabtagene Autoleucel (Arlo-Cel) in Relapsed and Refractory Multiple Myeloma (RRMM)	Saturday, December 6, 2025, 5:30-7:30 p.m.
2234	Measurable Residual Disease in Newly Diagnosed Multiple Myeloma: Experience from a Large Cohort from an Academic Medical Center	Saturday, December 6, 2025, 5:30-7:30 p.m.
2254	Safety and Efficacy of Linvoseltamab (LINV0) Combined with Anti-CD38 Monoclonal Antibodies (Mabs) Daratumumab (Dara) or Isatuximab (Isa) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the Multicohort, Phase 1B LINKER-MM2 Trial	Saturday, December 6, 2025, 5:30-7:30 p.m.
2260	Impact of Belantamab Mafodotin–Containing Regimens on Renal Function in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Mild/Moderate Renal Impairment in the DREAMM-7 and DREAMM-8 Trials	Saturday, December 6, 2025, 5:30-7:30 p.m.
2262	Long-Term Responders from the Phase 3 DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma	Saturday, December 6, 2025, 5:30-7:30 p.m.
2264	Deep Responses and Durable Outcomes in Patients Treated with Belantamab Mafodotin Plus Pomalidomide and Dexamethasone from Long-Term Follow-Up of The Phase 3 DREAMM-8 Study	Saturday, December 6, 2025, 5:30-7:30 p.m.
2265	Patients with Relapsed/Refractory Multiple Myeloma Who Achieved Sustained Minimal Residual Disease Negativity in the DREAMM-7 Trial	Saturday, December 6, 2025, 5:30-7:30 p.m.
4020	Comparative Analysis of Next Generation Flow (NGF) and Next Generation Sequencing Based clonoSEQ For MRD Detection in Multiple Myeloma Using Paired Bone Marrow Samples	Sunday, December 7, 2025, 6-8 p.m.
4173	CAR-T Cells Co-Targeting BCMA and CD19 in RRMM: Results from The UKMRA Phase 1 MCARTY Trial in Relapsed Refractory Multiple Myeloma	Sunday, December 7, 2025, 6-8 p.m.
4580	B-Cell Kinetics on Next Generation Sequencing After CAR T-Cell Therapy in Multiple Myeloma	Sunday, December 7, 2025, 6-8 p.m.

Abstracts Featuring clonoSEQ®
67th American Society of Hematology Annual Meeting & Exposition
Updated: November 24, 2025

5758	Low Conversion Rates to Minimal Residual Disease (MRD) Negativity Despite Improved IMWG Responses with Lenalidomide-Isatuximab Maintenance After Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma.	Monday, December 8, 2025, 6-8 p.m.
5763	Cytogenetic Subgroup Analysis of The Advance Trial: A Randomized Multi-Center Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) with or without Daratumumab (D) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)	Monday, December 8, 2025, 6-8 p.m.
5775	A Phase 2 Trial of Teclistamab Plus Daratumumab Combination Therapy for High-Risk Smoldering Multiple Myeloma: First Pre-Planned Analysis (The REVIVE Study)	Monday, December 8, 2025, 6-8 p.m.
5820	Functional High-Risk Relapsed/Refractory Multiple Myeloma (RRMM) Outcomes with Belantamab Mafodotin (Belamaf): DREAMM-7 and DREAMM-8 Subgroup Analysis	Monday, December 8, 2025, 6-8 p.m.
5824	Deepening Responses and MRD-Conversion in a Phase II Fixed-Duration Consolidation Trial of Elranatamab Post-Idecabtagene Vicleucel CAR-T Cell Therapy (EPIC) in Relapsed or Refractory Multiple Myeloma	Monday, December 8, 2025, 6-8 p.m.
5840	Belantamab Mafodotin (Belamaf) in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Patients (Pts) with Transplant-ineligible (TI) Newly Diagnosed Multiple Myeloma (NDMM): A Focus on Treatment Efficacy and Management/Resolution of Ocular Events in The Phase 1 DREAMM-9 Study	Monday, December 8, 2025, 6-8 p.m.
5846	clonoSEQ MRD Negativity at Day 90 is a Strong Predictor for Progression-Free and OverALL Survival After BCMA-Directed CAR T-Cell Therapy for Relapsed Multiple Myeloma.	Monday, December 8, 2025, 6-8 p.m.
6195	Implementation and Utility of Measurable Residual Disease (MRD) Testing for Multiple Myeloma Patients at a VA Medical Center	Monday, December 8, 2025, 6-8 p.m.
T-Acute Lymphoblastic Leukemia		
2838	Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages	Monday, December 8, 2025, 6-8 p.m.
Other		
1814	Efficacy and Tolerability of Bendamustine, Rituximab and Acalabutinib in Elderly Treatment Naïve Waldenström's Macroglobulinemia	Saturday, December 6, 2025, 5:30-7:30 p.m.
5431	T-Cell Clones of Uncertain Significance Are Prevalent in Cutaneous T-Cell Lymphomas	Monday, December 8, 2025, 6-8 p.m.